Completed PHASE3 INTERVENTIONAL NCT00171535

Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

A Study to Evaluate the Safety and Efficacy of Valsartan/Amlodipine Compared to Lisinopril/Hydrochlorothiazide Given Once Daily for 6 Weeks is Patients With Severe Hypertension

Sponsor: Novartis

Conditions Hypertension

Interventions valsartan/amlodipine

Updated 5 times since 2017 Last updated: Nov 7, 2011 Started: Oct 31, 2004 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypertension, this trial is completed. The trial is conducted by Novartis and has accumulated 5 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• East Hanover, United States